Association between Circulating Levels of IGF-1 and IGFBP-3 and Lung Cancer Risk: A Meta-Analysis

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Cao, Hongxin ^a   Wang, Guanghui ^a   Meng, Long ^a   Shen, Hongchang ^a   Feng, Zhen ^a   Liu, Qi ^a   Du, Jiajun ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR MARKER;

ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; HUMAN; LUNG CANCER; MULTIVARIATE ANALYSIS OF VARIANCE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STANDARD MEAN DIFFERENCE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869741103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049884     Document Type: Article

References (44)

1. Samani AA, Yakar S, LeRoith D, Brodt P, (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine reviews 28: 20-47.
2. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
3. Pollak MN, Schernhammer ES, Hankinson SE, (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518.
4. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE, (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215-244.
5. Macaulay VM, Everard MJ, Derrick Teale J, Trott PA, Van Wyk JJ, et al. (1990) Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer research 50: 2511.
6. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, et al. (1996) Insulin-like growth factor expression in human cancer cell lines. Journal of Biological Chemistry 271: 11477-11483.
7. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, et al. (1996) Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28: 619-637.
8. Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, et al. (2002) Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 62: 3530-3537.
9. Schairer C, McCarty CA, Isaacs C, Sue LY, Pollak MN, et al. (2010) Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort. Horm Cancer 1: 100-111.
10. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, et al. (2004) High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 22: 3104-3112.
11. Vatten LJ, Holly JM, Gunnell D, Tretli S, (2008) Nested case-control study of the association of circulating levels of serum insulin-like growth factor I and insulin-like growth factor binding protein 3 with breast cancer in young women in Norway. Cancer Epidemiol Biomarkers Prev 17: 2097-2100.
12. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE, (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13: 583-592.
13. Roddam AW, Allen NE, Appleby P, Key TJ, (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100: 170-183.
14. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S, (2007) Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer 120: 2007-2012.
15. Lukanova A, Toniolo P, Akhmedkhanov A, Biessy C, Haley NJ, et al. (2001) A prospective study of insulin-like growth factor-I, IGF-binding proteins-1,-2 and-3 and lung cancer risk in women. Int J Cancer 92: 888-892.
16. London SJ, Yuan JM, Travlos GS, Gao YT, Wilson RE, et al. (2002) Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 94: 749-754.
17. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, et al. (2002) Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev 11: 1413-1418.
18. Wakai K, Ito Y, Suzuki K, Tamakoshi A, Seki N, et al. (2002) Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: a case-control study nested in the Japan Collaborative Cohort (JACC) Study. Jpn J Cancer Res 93: 1279-1286.
19. Ahn J, Weinstein SJ, Snyder K, Pollak MN, Virtamo J, et al. (2006) No association between serum insulin-like growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 15: 2010-2012.
20. Morris JK, George LM, Wu T, Wald NJ, (2006) Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br J Cancer 95: 112-117.
21. Bhatavdekar JM, Patel DD, Chikhlikar PR, Mehta RH, Vora HH, et al. (1994) Levels of circulating peptide and steroid hormones in men with lung cancer. Neoplasma 41: 101-103.
22. Lee DY, Kim SJ, Lee YC, (1999) Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. Journal of Korean Medical Science 14: 401-404.
23. Wu XF, Yu H, Amos CI, Hong WK, Spitz MR, (2000) Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. Journal of the National Cancer Institute 92: 737-743.
24. Wang H, Wan YX, Zhang QK, (2004) [Significance and expression of insulin-like growth factor 1 and IGF binding protein 3 in serum of patients with lung cancer]. Ai Zheng 23: 710-714.
25. Unsal E, Koksal D, Yurdakul AS, Atikcan S, Cinaz P, (2005) Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer. Respiratory Medicine 99: 559-565.
26. Izycki T, Chyczewska E, Naumnik W, Ossolinska M, (2006) Serum levels of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy. Oncol Res 16: 49-54.
27. Langholz B (2005) Case-Control Study, Nested. Encyclopedia of Biostatistics.
28. Nahler G (2009) nested case-control studies. Dictionary of Pharmaceutical Medicine: 120-120.
29. Ernster VL, (1994) Nested case-control studies. Preventive Medicine 23: 587-590.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
31. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
32. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
33. Patsopoulos NA, Evangelou E, Ioannidis JP, (2008) Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 37: 1148-1157.
34. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
35. A T, (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 47: 15-17.
36. Wu X, Yu H, Amos CI, Hong WK, Spitz MR, (2000) Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst 92: 737-743.
37. Shi R, Berkel HJ, Yu H, (2001) Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 85: 991-996.
38. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, et al. (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124: 2416-2429.
39. Sugumar A, Liu YC, Xia Q, Koh YS, Matsuo K, (2004) Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer 111: 293-297.
40. Key TJ, Appleby PN, Reeves GK, Roddam AW, (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11: 530-542.
41. Duan QH, Wang ZG, Zhu GB, Lu ZX, Shi LY, et al. (2005) [Study on the relations between serum insulin-like growth factor-1, insulin-like growth factor binding protein-3 and colorectal cancer: a meta-analysis]. Zhonghua Liu Xing Bing Xue Za Zhi 26: 132-134.
42. Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, et al. (2010) Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 126: 1702-1715.
43. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, et al. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353.
44. Chen B, Liu S, Xu W, Wang X, Zhao W, et al. (2009) IGF-I and IGFBP-3 and the risk of lung cancer: a meta-analysis based on nested case-control studies. J Exp Clin Cancer Res 28: 89.